Remove tag launch
article thumbnail

Biogen’s Alzheimer’s drug: What’s the price tag on hope?

World of DTC Marketing

After aducanumab showed promise in 2016, Biogen launched two late-stage trials — then stopped them halfway through, in March 2019, when an analysis concluded the studies would not reach their goal of slowing cognitive and functional impairment in participants. Will they follow the science or will they put a price tag on hope?

article thumbnail

What is Biogen and can they repair their reputation?

World of DTC Marketing

More importantly, they felt the company should never have launched Aduhelm. Then, against the advisory panel’s advice, Aduhelm was approved, but insiders within the industry criticized both the FDA and Biogen weren’t sold on the drug or its price tag. 3hree: Top executives who supported the launch need to be shown the exit.

Insurance 222
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The current pharma business model is unsustainable

World of DTC Marketing

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. COVID-19 has not impacted the number of launches in the oncology space, as 2020 and 2021 have seen similar rates of drug launches as in 2019.

Pharma 210
article thumbnail

The Ultimate Guide to Healthcare SEO: 3 Techniques Your Website's Organic Marketing Needs

Healthcare Success

In addition to improving website content, SEO is achieved by optimizing several on-page and off-page elements like header tags, meta descriptions, image tags, URLs, high-quality backlinks, and social engagement. Optimize Description Tags Meta descriptions appear beneath the title tags in SERPs and summarize the web page’s content.

article thumbnail

bluebird bio wins back-to-back landmark FDA approvals for first-in-class gene therapies

Pharmaceutical Technology

Spark Therapeutics’ Luxturna, indicated for inherited retinal disease (IRD), was the first gene therapy to be approved, in 2017, with a price tag of $850,000 for each eye. They usually face resistance from insurers and may struggle to gain coverage at launch.

FDA 115
article thumbnail

BD partners with Biocorp on connected self-injection devices

pharmaphorum

Medtech giant Beckton Dickinson (BD) has signed a deal with France’s Biocorp to use the latter’s near-field communication (NFC) tags in injectable devices. The Injay tag can confirm a complete injection and transfer that information via an NFC reader to a smartphone or tablet for review by a healthcare professional.

article thumbnail

Pioneering the Path Pre- and Post-Launch Strategies

PM360

Understanding the “why” before the “how” as Med Affairs charts the course for pre- and post-launch strategies. With a focus on patient-centricity, data-driven insights, and collaborative partnerships across the healthcare ecosystem, it’s redefining the playbook for market shaping and building advocacy for a product pre- and post-launch.

Medical 52